Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
Rhea-AI Summary
Sangamo (NASDAQ: SGMO) announced its common stock will transition from The Nasdaq Capital Market to the OTCQB Venture Market at the open of trading on May 5, 2026, after receiving a Nasdaq notice related to minimum bid price non-compliance.
The company plans to request a hearing to appeal Nasdaq's delisting determination, has secured OTCQB quotation approval under the existing symbol SGMO, and says the transition is not expected to materially impact operations. Sangamo is pursuing additional capital and evaluating strategic options; details will be provided if definitive agreements are executed.
Positive
- OTCQB quotation approved for SGMO beginning May 5, 2026
- Company intends to appeal Nasdaq delisting decision
- Focused on raising additional capital and strategic options
Negative
- Expected suspension of Nasdaq trading at open on May 5, 2026
- Delisting due to minimum bid price non-compliance
News Market Reaction – SGMO
In the Apr 29 session, SGMO declined 33.93%, reflecting a significant negative market reaction. Argus tracked a trough of -41.3% from its starting point during tracking. Our momentum scanner triggered 25 alerts that day, indicating elevated trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Earnings and update | Negative | -19.7% | Reported 4Q/FY25 net losses and limited cash runway with continued funding needs. |
| Mar 19 | Earnings call notice | Neutral | -2.7% | Announced timing and access details for upcoming 4Q and FY25 earnings call. |
| Mar 09 | Clinical BLA progress | Positive | +8.7% | Advanced rolling BLA for ST-920 in Fabry disease with supportive STAAR data. |
| Feb 03 | Clinical data update | Positive | -7.6% | Presented detailed STAAR Phase 1/2 data and rolling BLA plan for ST-920. |
| Feb 03 | Equity offering | Negative | -31.3% | Priced ~$25M underwritten offering of shares and pre-funded warrants with warrants. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent SGMO news often saw negative reactions to financings and earnings, while positive clinical updates produced mixed price responses.
Over the last few months, Sangamo has balanced meaningful clinical advances with significant financial strain. Positive Fabry disease data and BLA progress on ST-920 (e.g., March 9, 2026) drew an 8.66% gain, but similar data on February 3, 2026 coincided with a 7.64% drop. Dilutive financing on February 3, 2026 led to a -31.33% move, and full-year 2025 results on March 30, 2026 saw shares fall 19.66%. Against this backdrop, today’s trading venue downgrade follows a pattern of market concern around balance-sheet and listing risks.
Key Terms
otcqb venture market financial
minimum bid price requirement regulatory
form 8-k regulatory
securities and exchange commission regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026
RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market to the OTCQB Venture Market on Tuesday, May 5, 2026. This transition follows the receipt by Sangamo of a notice from The Nasdaq Stock Market LLC indicating that Sangamo’s common stock will be delisted from the Nasdaq Capital Market due to non-compliance with Nasdaq’s minimum bid price requirement. Sangamo intends to request a hearing from Nasdaq to appeal the delisting determination. The hearing will not stay the suspension of trading of Sangamo’s common stock, and trading of Sangamo’s common stock on The Nasdaq Capital Market is expected to be suspended at the open of trading on May 5, 2026.
Sangamo has secured approval for its common stock to be quoted on the OTCQB Venture Market, operated by OTC Markets Group. Sangamo expects its common stock to begin trading on the OTCQB Venture Market under its existing trading symbol, SGMO, at the open of trading on Tuesday, May 5, 2026. For quotes or additional information, investors may visit www.otcmarkets.com.
The transition of trading onto the OTCQB Venture Market is not expected to result in material impacts to Sangamo’s business or operations. Sangamo remains focused on pursuing opportunities to raise additional capital, including an assessment of all strategic options to maximize the value of its assets, and throughout the process has been advised by a global investment bank. Sangamo is currently negotiating multiple potential business development transactions and expects to share details on these potential transactions if and when definitive agreements are executed.
Sangamo will continue to provide updates on business progress and financial results in accordance with applicable Securities and Exchange Commission regulations. Additional information related to this announcement will be included in a Current Report on Form 8-K to be filed with the SEC.
About Sangamo Therapeutics
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment. To learn more, visit www.sangamo.com and connect with us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, statements relating to Sangamo’s expectations concerning the transition of Sangamo’s common stock to the OTCQB Venture Market and the timing and impact thereof, expectations regarding a potential hearing to appeal Nasdaq’s delisting determination, Sangamo’s plans to pursue additional opportunities to raise capital and maximize the value of its assets and the potential for execution of definitive agreements in respect of business development transactions. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to Sangamo’s lack of capital resources and need for substantial additional funding to execute its operating plan and to continue to operate as a going concern, including the risk that Sangamo will be unable to secure a significant partnership or other transaction, in particular for its Fabry disease program, providing for substantial upfront funding in the very near term necessary to fund its operations and operate as a going concern; the risk that Sangamo will be unsuccessful in appealing the delisting determination; the effects of macroeconomic factors or financial challenges, including as a result of the ongoing overseas conflicts, tariffs, geopolitical instability, inflation and fluctuations in interest rates, on the global business environment; the uncertain research and development process, including the results of clinical trials; the regulatory approval process for product candidates; and the potential for technological developments that obviate technologies used by Sangamo. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2025. Forward-looking statements contained in this announcement are made as of this date, and Sangamo undertakes no duty to update such information except as required under applicable law.
Investor Relations and Media Inquiries
Louise Wilkie
ir@sangamo.com
media@sangamo.com
